Key Events This Week
18 May: Stock opens at ₹789.95, up 0.82% despite Sensex decline
19 May: Downgrade to Sell announced amid technical weakness and financial setbacks
20 May: Formation of Golden Cross signals potential bullish breakout
21 May: Technical momentum shifts to mildly bullish despite price decline
22 May: Quality grade upgraded to Excellent; rating upgraded to Buy
18 May 2026: Positive Start Despite Broader Market Weakness
Anthem Biosciences began the week on a positive note, closing at ₹789.95, up ₹6.45 or 0.82%, while the Sensex declined 0.35% to 35,114.86. The stock’s outperformance on a day of market weakness suggested initial investor confidence. Trading volume was moderate at 29,508 shares, indicating steady participation. This positive momentum, however, was short-lived as subsequent days brought mixed signals.
19 May 2026: Downgrade to Sell Amid Technical and Financial Concerns
On 19 May, MarketsMOJO downgraded Anthem Biosciences from 'Hold' to 'Sell', citing deteriorating technical indicators and disappointing quarterly financial results. The stock closed at ₹787.10, down 0.36% from the previous day, while the Sensex gained 0.25%. The downgrade highlighted a 24.2% decline in profit before tax and a 14.1% drop in profit after tax for Q3 FY25-26, alongside valuation concerns with a high price-to-book ratio of 15.6. Despite strong long-term growth metrics, the recent earnings softness and technical weakness prompted a cautious stance.
20 May 2026: Golden Cross Formation Signals Potential Bullish Reversal
The stock experienced a significant technical event on 20 May as its 50-day moving average crossed above the 200-day moving average, forming a Golden Cross. This classic bullish signal suggested a potential long-term upward momentum shift. Despite this, the stock price declined 0.87% to ₹780.25 amid heavy trading volume of 114,003 shares. The Sensex rose 0.28% that day. The Golden Cross was supported by bullish daily moving averages and weekly MACD, although monthly On-Balance Volume remained bearish, indicating some caution in volume trends.
This week's revealed pick, a Large Cap from Public Banks with TARGET PRICE, is already showing movement! Get the complete analysis before it's too late.
- - Target price included
- - Early movement detected
- - Complete analysis ready
21 May 2026: Technical Momentum Shifts to Mildly Bullish Despite Price Drop
On 21 May, Anthem Biosciences’ technical momentum improved, shifting from mildly bearish to mildly bullish. The weekly MACD turned positive, and daily moving averages aligned bullishly, supported by Bollinger Bands indicating stabilising volatility. However, the stock price fell 1.42% to ₹769.15 on heavy volume of 316,718 shares, while the Sensex gained 0.12%. Mixed volume indicators, including a bearish monthly OBV, suggested that price gains were not fully supported by volume, warranting cautious optimism.
22 May 2026: Quality Grade Upgraded to Excellent and Rating Raised to Buy
The week concluded with a significant upgrade in Anthem Biosciences’ quality grade from Good to Excellent, reflecting strong financial metrics such as a 29.8% sales CAGR and 44.32% EBIT growth over five years. The company’s return on capital employed averaged 32.62%, with a pristine debt profile and an EBIT to interest coverage ratio of 76.10. Institutional investors increased their stake to 12.83%, signalling confidence. Correspondingly, MarketsMOJO upgraded the stock’s rating from Sell to Buy. Despite a 1.42% price decline to ₹769.15 on the day, the stock’s year-to-date return stood at 18.14%, outperforming the Sensex’s negative 11.78% return.
Anthem Biosciences Ltd caught your attention? Explore our comprehensive research report with in-depth analysis of this mid-cap stock – fundamentals, valuations, financials, and technical outlook!
- - Comprehensive research report
- - In-depth mid-cap analysis
- - Valuation assessment included
Daily Price Performance Compared to Sensex
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-05-18 | Rs.789.95 | +0.82% | 35,114.86 | -0.35% |
| 2026-05-19 | Rs.787.10 | -0.36% | 35,201.48 | +0.25% |
| 2026-05-20 | Rs.780.25 | -0.87% | 35,299.20 | +0.28% |
| 2026-05-21 | Rs.769.15 | -1.42% | 35,340.31 | +0.12% |
| 2026-05-22 | Rs.776.55 | +0.96% | 35,413.94 | +0.21% |
Key Takeaways
Positive Signals: Anthem Biosciences demonstrated strong long-term growth with a 29.8% sales CAGR and 44.32% EBIT growth, supported by excellent return ratios (ROCE 32.62%, ROE 19.93%) and a net-debt free balance sheet. The formation of a Golden Cross and subsequent shift to mildly bullish technical momentum indicate potential for upward price movement. The upgrade to an Excellent quality grade and Buy rating by MarketsMOJO reflects improved fundamentals and operational efficiency. Institutional investor stake increased to 12.83%, signalling confidence.
Cautionary Notes: The stock underperformed the Sensex over the week, declining 0.89% versus a 0.50% gain in the benchmark. Early-week downgrade to Sell was driven by disappointing quarterly earnings with a 24.2% drop in PBT and elevated valuation metrics (P/B ratio 15.6, P/E 87.60) raising concerns about overvaluation. Mixed volume indicators, including bearish monthly OBV, suggest that price gains may lack strong volume support. Price volatility remains elevated, with a wide 52-week range from ₹579.45 to ₹873.25.
Conclusion
The week for Anthem Biosciences Ltd was characterised by a complex blend of technical shifts, fundamental reassessments, and valuation debates. While the stock faced near-term pressure and a downgrade early in the week, technical indicators such as the Golden Cross and a shift to mildly bullish momentum, combined with a quality grade upgrade and a Buy rating reinstatement, suggest improving underlying strength. The company’s robust financial metrics and operational efficiency provide a solid foundation, though elevated valuation and mixed volume trends warrant cautious monitoring. Investors should watch for confirmation of sustained earnings growth and volume support to validate the emerging bullish signals amid a volatile market backdrop.
Only Rs. 20,999 - Get MojoOne + Stock of the Week for 3 Years Get 71% Off →
